炎症性肠病（IBD）的微生态治疗逐渐成为近年来的研究热点，越来越多的实验研究为微生态制剂在IBD中的应用提供了重要理论支撑，且取得了显著的临床应用成效，某些微生态制剂已被推荐用于轻中度溃疡性结肠炎（UC）病人的维持缓解治疗和病人术后贮袋炎的预防和维持缓解治疗。结合最新的研究结果对UC和克罗恩病（CD）术后病人微生态治疗的现状进行分析，提出未来研究方向，期待更加规范的大规模临床研究进一步验证IBD微生态治疗的有效性和安全性，指导临床应用。

Probiotics in the application of inflammatory bowel disease        QIN Huan-long*，CHEN Hong-qi.  *Department of General Surgery, Shanghai Tenth People’s Hospital, Shanghai 200072, China
Corresponding author ：QIN Huan-long，E-mail：hlqin@sjtu.edu.cn
Abstract    Probiotic treatment of inflammatory bowel disease (IBD) has gradually become the hot issue in recent years. A growing number of experimental studies provide the important theoretical support for the application of probiotics in IBD, and achieved significant clinical effectiveness. Some probiotics have been recommended for maintenance of remission in mild to moderate UC patients and preventing and maintaining remission of pouchitis in UC patients pouch inflammation of postoperative UC patients. This paper will combine the latest results to evaluate the clinical efficacy in the treatment of UC, CD and postoperative patients with probiotics, and propose directions for future research, looking forward to more strictly large-scale clinical trials to further verify the efficacy and safety of probiotics in the treatment of IBD, and to guide clinical application of probiotics.